v3.25.4
Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Income Tax Rate to Effective Income Tax Rate Percent 2025 (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Amount      
Income tax at the statutory tax rate $ (78,482) $ 58,794 $ 37,241
Domestic tax effects      
Effects of cross-border tax laws 29,812    
Non-deductible financing costs      
Non-deductible financing costs   22,437 15,705
Other 963    
Foreign tax effects      
Statutory tax rate difference   38,346 (7,763)
Non-deductible acquired in-process research and development expense 187,346    
Change in valuation allowance (199,907) 201,996 75,081
Research and orphan drug tax credits (35,329) (65,255) (49,900)
Foreign derived intangible income benefit (28,623) (39,470) (42,400)
Non-deductible compensation 8,856 10,889 14,092
Non-deductible contingent consideration payments 7,641    
State and local income tax, net of federal benefit (5,477)    
Tax deficiencies/(excess tax benefits) from share-based compensation 5,050 18,074 3,959
Other   3,913 3,661
Patent box incentive benefit (60,993) (65,413) (13,862)
Deduction on subsidiary equity (90,788) (180,460) (153,655)
Worldwide changes in unrecognized tax benefits (6,439) 9,767 (12,612)
Total income tax expense (benefit) $ (272,443) (91,429) (119,912)
Percent      
Income tax at the statutory tax rate 12.50%    
Domestic tax effects      
Effects of cross-border tax laws (4.70%)    
Non-taxable/non-deductible items      
Other (0.20%)    
Foreign tax effects      
Non-deductible acquired in-process research and development expense (29.80%)    
Change in valuation allowance 31.80%    
Research and orphan drug tax credits 5.60%    
Foreign Derived Intangible Income benefit 4.60%    
Non-deductible compensation (1.40%)    
Non-deductible contingent consideration payments (1.20%)    
State and local income tax, net of federal benefit 0.90%    
Tax deficiencies/(excess tax benefits) from share-based compensation (0.80%)    
Patent box incentive benefit 9.70%    
Deduction on subsidiary equity 14.50%    
Worldwide changes in unrecognized tax benefits 0.90%    
Total income tax benefit 43.40%    
Ireland      
Non-deductible financing costs      
Non-deductible financing costs $ 7,070    
Non-taxable/non-deductible items      
Non-deductible financing costs (1.10%)    
United States      
Foreign tax effects      
Statutory tax rate difference $ (74,137)    
Other 525    
Total income tax expense (benefit) $ (254,537) (40,142) (69,267)
Foreign tax effects      
Statutory tax rate difference 11.80%    
Other (0.10%)    
United Kingdom      
Non-deductible financing costs      
Non-deductible financing costs $ 7,222    
Foreign tax effects      
Statutory tax rate difference (30,766)    
Other 2,107    
Total income tax expense (benefit) $ (113,831) (114,393) (142,512)
Non-taxable/non-deductible items      
Non-deductible financing costs (1.20%)    
Foreign tax effects      
Statutory tax rate difference 4.90%    
Other (0.30%)    
Italy      
Foreign tax effects      
Statutory tax rate difference $ 7,603    
Other $ 2,006    
Patent box incentive benefit   (40,900)  
Foreign tax effects      
Statutory tax rate difference (1.20%)    
Other (0.30%)    
Malta      
Foreign tax effects      
Statutory tax rate difference $ 64,010    
Other $ 827    
Foreign tax effects      
Statutory tax rate difference (10.20%)    
Other (0.10%)    
Other foreign jurisdictions      
Foreign tax effects      
Statutory tax rate difference $ 7,460    
Total income tax expense (benefit) $ 34,118 $ (14,552) $ 25,443
Foreign tax effects      
Statutory tax rate difference (1.20%)